Study Groups

The Acute Lymphoblastic Leukaemia (ALL) Study Group, chaired by Dr Clare Rowntree, develops research into Acute lymphoblastic leukaemia, a type of blood cancer that starts from young white blood cells called lymphocytes in the bone marrow.

Members:

Clare Rowntree, Cardiff and Vale University Health Board (CVUHB) (study group chair)

Thomas Fox, University College London Hospitals NHS Foundation Trust (UCLH)

Rachael Hough, University College London Hospitals NHS Foundation Trust (UCLH)

Amy Kirkwood, Senior Statistician, Cancer Research UK (CRUK) London – Clinical Trials Unit @ University College London (UCL)

David Marks, University Hospitals Bristol NHS Foundation Trust

Andrew McMillan, Consultant Haematologist, Nottingham University Hospitals NHS Trust

Tobias Menne, Newcastle upon Tyne Hospitals NHS Foundation Trust

Anthony Moorman, Professor of Genetic Epidemiology, Newcastle University

Nicholas Morley, Sheffield Teaching Hospitals NHS Foundation Trust

Gillian Murphy, NCRI Consumer Forum member

Oliver Ottmann, Professor and Head of Haematology, Cardiff University

Bella Patel, University College London (UCL)

John Reeve, NCRI Consumer Forum member

The Acute Myeloid Leukaemia (AML) Study Group, chaired by Professor Charles Craddock, develops research into acute myeloid leukaemia, a type of blood cancer that starts from white blood cells called granulocytes or monocytes in the bone marrow.

Members:

Charles Craddock, Director of the Blood and Marrow Transplant Unit & Professor of Haemato-oncology, University of Birmingham (study group chair)

Steven Knapper, Honorary Consultant Haematologist, Cardiff University (study group deputy chair)

Sahra Ali, Hull Royal Infirmary

David Bowen, Leeds Teaching Hospitals NHS Trust – Leeds General Infirmary

Richard Castle, NCRI Consumer Forum member

Jane Leahy, NCRI Consumer Forum member

Jamie Cavenagh, Queen Mary University of London

Richard Clark, University of Liverpool

Mhairi Copland, Professor of Translational Haematology and Honorary Consultant, University of Glasgow

Dominic Culligan, NHS Grampian – Aberdeen Royal Infirmary

Mike Dennis, Consultant Haematologist, Christie NHS Foundation Trust

Sylvie Freeman, King’s College London (KCL)

Ann Hunter, King’s College London (KCL)

Brian Huntly, University of Cambridge

Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust

Harpreet Kaur, Sheffield Teaching Hospitals NHS Foundation Trust

Asim Khwaja, University College London (UCL)

Panos Kottaridis, University College London Hospitals NHS Foundation Trust (UCLH)

Robert Lown, University Hospital Southampton NHS Foundation Trust – Princess Anne Hospital

Mary McMullin, Queen’s University Belfast

Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust

Francis Mussai, Clinical Senior Lecture Consultant, University of Birmingham

Paresh Vyas, Consultant Haematology, MRC Weatherall Institute of Molecular Medicine

The Chronic Lymphocytic Leukaemia (CLL) Study Group, chaired by Dr Piers Patten, develops research into chronic lymphocytic leukaemia, cancer that develops from lymphoid blood stem cells.

Members:

Piers Patten, Clinical Senior Lecturer, Kings College London (study group chair)

Talha Munir, Consultant Haematologist, The Leeds Teaching Hospitals (study group deputy chair)

Anna Schuh, University of Oxford

David Allsup, Hull Royal Infirmary

Adrian Bloor, Christie NHS Foundation Trust

Dena Cohen, University of Leeds

Stephen Devereux, King’s College London (KCL)

Martin Dyer, Professor of Haemato-Oncology, University Hospitals of Leicester NHS Trust

Dima El-Sharkawi, , No affiliation

Chris Fegan, Cardiff and Vale University Health Board (CVUHB)

Francesco Forconi, University of Southampton

Christopher Fox, Consultant Haematologist, Nottingham University Hospitals NHS Trust

Peter Hillmen, Professor of Experimental Haematology, University of Leeds

Parag Jasani, No affiliation

Ben Kennedy, University Hospitals of Leicester NHS Trust

Scott Marshall, South Tyneside and Sunderland NHS Foundation Trust

Nicolas Martinez, Nottingham University Hospitals NHS Trust

Chris Pepper, Cardiff University

Andrew Pettitt, Professor of Haematology Molecular and Clinical Cancer Medicine, University of Liverpool

Guy Pratt, University of Birmingham

Nick York, Trustee, CLL Support Association, CLL Support Association

The Chronic Myeloid Leukaemia (CML) Study Group, chaired by Dr Dragana Milojkovic, develops research into chronic myeloid leukaemia, a type of cancer that develops from myeloid blood stem cells.

Members:

Dragana Milojkovic, Consultant Haematologist, Imperial College London (study group chair)

Kate Rothwell, Consultant in Haematology (study group deputy chair)

Jane Apperley, Professor of Haemato-Oncology, Imperial College London

Jenny Byrne, University of Nottingham

Richard Clark, University of Liverpool

Mhairi Copland, Professor of Translational Haematology and Honorary Consultant, University of Glasgow

Sandy Craine, NCRI Consumer Representative

Joanne Ewing, Heart of England NHS Foundation Trust

Paolo Gallipolli, Clinical Senior Lecturer in Haemato-Oncology, Queen Mary University Hospital, Barts and the London

Andrew Goringe, King’s College London (KCL)

Brian Huntly, University of Cambridge

Oliver Ottmann, Professor and Head of Haematology, Cardiff University

Seonaid Pye, Consultant Haematologist, University Hospital Southampton NHS Foundation Trust

Anupama Rao, Consultant in Paediatric Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust

Andres Virchis, Consultant Haematologist, University College London Hospitals NHS Foundation Trust (UCLH)

Yngvar Floisand, Consultant Haematologist, Clatterbridge Cancer Centre – Liverpool

The Myelodysplastic Syndromes (MDS) Study Group, chaired by Dr Beth Payne, develops research into conditions that can occur when the blood-forming cells in the bone marrow become abnormal.

Members:

Beth Payne, Consultant Haematologist, University College London (UCL) (study group chair)

Lynn Quek, Clinician Scientist and Consultant Haematologist, Kings College London, (study group deputy chair)

Sally Killick, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust

Rebecca Bishop, Senior Trial Coordinator, University of Birmingham

Chris Bunce, Professor of Translational Cancer Biology, University of Birmingham

Catherine Cargo, King’s College London (KCL)

Jamie Cavenagh, Queen Mary University of London

John Chadwick, Clinical Research Fellow, Cancer Research UK Manchester Institute

Wei Chan, Doctoral Clinical Fellow, The Francis Crick Institute

Tim Chevassut, King’s College London (KCL)

Oni Chowdhury, Consultant Haematologist, University of Oxford

Tom Coats, Consultant Haematologist, Royal Devon and Exeter NHS Trust

Dominic Culligan, NHS Grampian – Aberdeen Royal Infirmary

Simone Green, King’s College London (KCL)

Catherine Hockings, Consultant Haematologist, Kings College London Hospital NHS Foundation Trust

Aimie Houlton, King’s College London (KCL)

Wendy Ingram, King’s College London (KCL)

Steven Jenkins, Consultant Haematologist, The Dudley Group NHS Foundation Trust 

Harpreet Kaur, Sheffield Teaching Hospitals NHS Foundation Trust

Primila Krishnamurthy, Consultant Haematologist, Kings College London (KLC)

Anjam Khan, Consultant Haematologist, Leeds Teaching Hospital NHS Foundation Trust

Austin Kulasekararaj, King’s College London (KCL)

Tom McKerrell, Consultant Haematologist, James Paget University Hospital

Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust

Juliet Mills, King’s College London (KCL)

Ken Mills, Queen’s University Belfast

Sreetharan Munisamy, Consultant Haematologist, East Kent Hospital University NHS Foundation Trust

Jennifer O’Sullivan, Clinical Research Fellow, University of Oxford

Jane Parker, Northampton General Hospital

Rachel Protheroe, Consultant Haematologist, University Hospital Bristol NHS Foundation Trust

Manoj Raghavan, Consultant Haematologist, University of Birmingham

Kavita Raj, Guy’s and St Thomas’ NHS Foundation Trust

Alexander Sternberg, , King’s College London (KCL)

Ian Thomas, Consultant Haematologist, Cardiff University

Sophie Wintrich, King’s College London (KCL)

Dan Wiseman, Cancer Research UK (CRUK) Manchester Institute

Simon Stanworth, Consultant Haematologist, University of Oxford

Alan Warren, Consultant Haematologist, University of Cambridge

Caroline Watson (Early Career Research Lead), Clinical Research Associate, University of Cambridge

The Myeloma Study Group, chaired by Dr Rakesh Popat, develops research into malignant tumours of the bone marrow.

Members:

Rakesh Popat, Consultant Haematologist, University College London Hospitals NHS Foundation Trust (UCLH) (study group chair)

Firas Abed, Royal Derby Hospital

John Ashcroft, Mid Yorkshire Hospitals NHS trust

Maria Atta, Imperial College Healthcare Trust

Holger Auner, Imperial College Healthcare Trust

Reuben Benjamin, King’s College London (KCL)

Jenny Bird, University Hospitals Bristol NHS Foundation Trust

Stella Bowcock, King’s College Hospital NHS Foundation Trust

Kevin Boyd, The Royal Marsden

Sarah Brown, University of Leeds

Ceri Bygrave, University Hospital Wales

David Cairns, University of Leeds

Jamie Cavenagh, Barts Health NHS Trust

Aris Chaidos, Imperial College Healthcare Trust

Andy Chantry, University of Sheffield

Mike Chapman, University of Cambridge

Charalampia Kyriakou, University College London Hospitals NHS Foundation Turst (UCLH)

Rups Chouduri, Royal Oldham Hospital

Gordon Cook, University of Leeds

Charles Crawley, Addenbrooke’s Hospital NHS Foundation Trust

Kirsty Cuthill, King’s College London (KCL)

Shirley D’sa, University College London Hospitals NHS Foundation Trust (UCLH)

Caroline Donoghue, Myeloma UK

Mark Drayson, University of Birmingham

Lydia Eccersley, Barts Health NHS Trust

Sarah Gooding, Oxford Centre of Haematology

Rachel Hall, Royal Bournemouth Hospital

Andrew Hall, University of Leeds

Hannah Hunter, University of Plymouth

Graham Jackson, University of Newcastle

Sally Jeans, Patient Representative

Matthew Jenner, University Hospital Southampton NHS Foundation Trust

John Jones, University of Sussex

Martin Kaiser, The Royal Marsden

Kamaraj Karunanithi, University Hospitals of North Midlands NHS Trust

Bhuvan Kishore, University Hospitals Birmingham

Lydia Lee, University College London Hospitals NHS Foundation Trust (UCLH)

Anand Lokare, University Hospitals Birmingham

Sally Moore, Oxford University

Inas Najjar, Guy’s and St Thomas’ NHS Foundation Trust

Catherine Olivier, University of Southampton

Kim Orchard, University Hospital Southampton NHS Foundation Trust

Chris Parrish, University of Leeds

Charlotte Pawlyn, The Institute of Cancer Research

Guy Pratt, University of Birmingham

Andrea Preston, University of Bristol

Neil Rabin, University College London Hospitals NHS Foundation Trust (UCLH)

Karthik Ramasamy, University of Oxford

Sadie Roberts, Leeds Institute of Clinical Trials Research

Charlotte Robertson, University of Aberdeen

Kara-Louise Royle, University of Leeds

Steve Schey, London Bridge Hospital

Jonathan Sive, University College London Hospitals NHS Foundation Trust (UCLH)

Dean Smith, University of Nottingham

John Snowden, Sheffield Teaching Hospitals NHS Foundation Trust

Richard Soutar, University of Glasgow

Matthew Streetly, Guy’s and St Thomas’ NHS Foundation Trust

Supratik Basu, The Royal Wolverhampton NHS Trust

Jane Tighe, Royal Aberdeen Hospitals

Kwee Yong, University College London Hospitals NHS Foundation Trust (UCLH)

The Myeloproliferative Neoplasms (MPN) Study Group, chaired by Dr Donal McLornan, develops research into blood cancers that occur when the body makes too many white or red blood cells or platelets.

Members:

Donal McLornan, Consultant Haematologist, King’s College London (KCL) (study group chair)

Bethan Psaila, Associate Professor of Haematology, University of Oxford (study group deputy chair)

Sahra Ali, Hull Royal Infirmary

Elizabeth Joanna Baxter, Senior Research Associate, University of Cambridge

Nauman Butt, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Peter Campbell, Head Of Cancer Genetics And Genomics, Wellcome Sanger Institute

Catherine Cargo, King’s College London (KCL)

Eibjilin Conneally, Leeds Teaching Hospitals NHS Trust

Nick Cross, University of Southampton

Mark Drummond, NHS Greater Glasgow and Clyde

Adam Mead, University of Oxford

Andrew Duncombe, King’s College London (KCL)

Joanne Ewing, Heart of England NHS Foundation Trust

Sonia Fox, University of Birmingham

Sebastian Francis, Sheffield Teaching Hospitals NHS Foundation Trust

Rebecca Frewin, No affiliation

Anna Godfrey, King’s College London (KCL)

Tony Green, University of Cambridge

Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust

Clodagh Keohane, Mercy University Hospital

Steven Knapper, Cardiff University

Jonathan Lambert, University College London Hospitals NHS Foundation Trust (UCLH)

Mary McMullin, Queen’s University Belfast

Dragana Milojkovic, Consultant Haematologist, Imperial College London

Jyoti Nangalia, University of Cambridge

Alisia O’Sullivan, King’s College London (KCL)

Deepti Radia, Guy’s and St Thomas’ NHS Foundation Trust

Ciro Rinaldi, United Lincolnshire Hospitals NHS Trust

Shekouhi Satareh, Guy’s and St Thomas’ NHS Foundation Trust

Mallika Sekhar, King’s College London (KCL)

Shamyla Siddique, Haematology Trials Team Leader, University of Birmingham

Tim Somervaille, Cancer Research UK (CRUK) Manchester Institute

Frances Wadelin, Nottingham University Hospitals NHS Trust

Jonathan Wallis, Newcastle upon Tyne Hospitals NHS Foundation Trust

Louise Wallis, Royal Brompton & Harefield NHS Foundation Trust

Claire Woodley, Guy’s and St Thomas’ NHS Foundation Trust